SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma

American Journal of Hematology

Volumn 88, Issue 3, 2013, Pages 185-192

  Zinzani, Pier Luigi ^a   Marchetti, Monia ^b   Billio, Atto ^c   Barosi, Giovanni ^d   Carella, Angelo Michele ^e   Lazzarino, Mario ^d   Martelli, Maurizio ^f   Rambaldi, Alessandro ^g   Rigacci, Luigi ^h   Tarella, Corrado ⁱ   Vitolo, Umberto ^j   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Ospedale Cardinal Massaia   (Italy)

^c Ospedale Civile di Bolzano   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g Divisione di Ematologia   (Italy)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ MAURIZIANO HOSPITAL   (Italy)

^j MOLINETTE HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG RESPONSE; FAILURE FREE SURVIVAL; FOLLICULAR LYMPHOMA; HEALTH CARE ORGANIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; MAINTENANCE THERAPY; NEUTROPENIA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR VOLUME; WATCHFUL WAITING;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; TIME FACTORS;

EID: 84874307199     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23372     Document Type: Article

References (79)

1. Barosi G, Carella A, Lazzarino M, et al.Management of nodal indolent (non marginal-zone) nonHodgkin's lymphoma: Practice guidelines from the Italian Society of Haematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation.Haematologica 2005;90:1237-1257.
2. Bosga-Bouer AG, van den Berg A, Haralambieva E, et al. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3b; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?Hum Pathol 2006;37:528-533.
3. Guyatt GH, Oxman AD, Vist GE, et al.GRADE: An emerging consensus on rating quality of evidence and strength of recommendations.Br J Med 2008;336:924-926.
4. Ferguson JH.The NIH consensus development program. The evolution of guidelines.Int J Technol Assess Health Care 1996;12:460-474.
5. Mauro FR, Bandini G, Barosi G, et al.SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.Leuk Res 2010;34:1576-1588.
6. Meignan M, Gallamini A, Haioun C, et al.Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010.Leuk Lymphoma 2010;51:2171-2180.
7. Tsukamoto N, Kojima M, Hasegawa M, et al.The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification.Cancer 2007;110:652-659.
8. Elstrom R, Guan L, Baker G, et al.Utility of FDG-PET scanning in lymphoma by WHO classification.Blood 2003;101:3875-3876.
9. Wöhrer S, Jaeger U, Kletter K, et al.18F-fluoro-deoxy-glucose positron emission tomography (18FFDG-PET) visualizes follicular lymphoma irrespective of grading.Ann Oncol 2006;17:780-784.
10. Janikova A, Bolcak K, Pavlik T, et al.Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma?Clin Lymphoma Myeloma 2008;8:287-293.
11. Le Dortz L, De Guibert S, Bayat S, et al.Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma.Eur J Nucl Med Mol Imaging 2010;37:2307-2314.
12. Bishu S, Quigley JM, Bishu SR, et al.Predictive value and diagnostic accuracy of F-18-fluoro-deoxyglucose positron emission tomography treated grade 1 and 2 follicular lymphoma.Leuk Lymphoma 2007;48:1548-1555.
13. Jerusalem G, Beguin Y, Naijar F, et al.Positron emission tomography (PET) with 18Ffluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).Ann Oncol 2011;12:825-830.
14. Imataki O, Tamai Y, Yokoe K, et al.The utility of FDG-PET for managing patients with malignant lymphoma: Analysis of data from a single cancer center.Intern Med 2009;48:1509-1513.
15. Wirth A, Foo M, Seymour JF, et al.Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma.Int J Radiat Oncol Biol Phys 2008;71:213-219.
16. Karam M, Novak L, Cyriac J, et al.Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.Cancer 2006;107:175-183.
17. Hofman MS, Hicks RJ.Imaging in follicular NHL.Best Pract Res Clin Haematol 2011;24:165-177.
18. Blum RH, Seymour JF, Wirth A, et al.Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.Clin Lymphoma 2003;4:43-49.
19. Scott AM, Gunawardana DH, Wong J, et al.Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: Results of a multicenter prospective study.Eur J Nucl Med Mol Imaging 2009;36:347-353.
20. Pakos EE, Fotopoulos AD, Ioannidis JP.18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta-analysis.J Nucl Med 2005;46:958-963.
21. Rambaldi A, Carlotti E, Oldani E, et al.Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma.Blood 2005;105:3428-3433.
22. van Oers MH, Tönnissen E, Van Glabbeke M, et al.BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: Results of a prospective randomized EORTC 20981 phase III intergroup study.J Clin Oncol 2010;28:2246-2252.
23. Solal-Celigny P, Roy P, Colombat P, et al.Follicular Lymphoma international prognostic index.Blood 2004;104:1258-1265.
24. Federico M, Bellei M, Marcheselli L, et al.Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.J Clin Oncol 2009;27:4555-4562.
25. Ardeshna KM, Smith P, Norton A, et al.Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomized controlled trial.Lancet 2003;362:516-522.
26. Solal-Celigny P, Lepage E, Brousse N, et al.Doxorubicin containing regimen with or without interferon alfa 2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaire 86 trial.J Clin Oncol 1998;16:2332-2338.
27. Ardeshna K, Qian W, Smith P, et al.An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a).A preliminary analysis. Blood (ASH Annual Meeting Abstracts)2010;116:6.
28. Ardeshna KM, Quian W, Stephens R, et al.Preliminary results of quality of life (QOL) analyses from the intergroup phase III randomized trial of Rituximab vs.a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma (FL). Ann Oncol 2011;22:19.
29. Lowry L, Smith P, Qian W, et al.Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomized phase III trial.Radiother Oncol 2011;100:86-91.
30. Herold M, Pasold R, Srock S, et al.Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and MantleCell-lymphoma (MCL).ASH Annual Meeting Abstracts 2004; 104:584.
31. Hiddman W, Kneba M, Dreyling M, et al.Frontline therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.Blood 2005;106:3725-3732.
32. Buske C, Hoster E, Dreyling M, et al.Rituximab in combination with CHOP in patients with follicular lymphoma: Analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group (GLSG) after a follow up of 58 months.Blood (ASH Annual Meeting Abstracts)2008;112:2599.
33. Marcus R, Imrie K, Belch A, et al.CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.Blood 2005;105:1417-1423.
34. Federico M, Luminari S, Dondi A, et al. R-CVP vs. R-CHOP vs. R-FM for the initial treatment of patients with advanced stage follicular lymphoma. Preliminary results of FOLL05 trial. Ann Oncol 2011;22:135.
35. Rummel M, Niederle N, Maschmeyer G, et al.Bendamustine plus rituximab in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the AtiL (Study Group Indolent Lymphomas, Germany).Blood 2009;114:404.
36. Al Khabori M, de Almeida JR, Guyatt GH, et al.Autologous stem cell transplantation in follicular lymphoma: A systematic review and meta-analysis.J Natl Cancer Inst 2012;104:18-28.
37. Ladetto M, De Marco F, Benedetti F, et al.Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL).Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008;111:4004-4013.
38. Trotman I, Fournier M, Lam T, et al.Positron emission tomography-Computed tomography (PETCT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants.J Clin Oncol 2011;29:3194-3200.
39. Cheson BD, Horning SJ, Coiffier B, et al.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas.NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
40. Cheson BD, Pfistner B, Juweid ME, et al.Revised response criteria for malignant lymphoma.J Clin Oncol 2007;25:579-586.
41. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomized controlled trial. Lancet 2011;377:42-51.
42. Morschhauser F, Radford J, van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90Ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 2008;32:5156-5150.
43. Jacobs SA, Swerdlow SH, Kant J, et al.Phase III trial of short course CHOP-R followed by 90 yibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.Clin Cancer Res 2008;14:7088-7094.
44. McLaughlin P, Neelapu S, Fanale M, et al. R-FND followed by radioimmunotherapy for high-risk follicular lymphoma. Blood 2008;112:3056a (abstract).
45. Hainsworth JD, Spiegel DR, Markus TM, et al.Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first line treatment for patients with follicular non-Hodgkin lymphoma: A phase II trial of the Sarah Cannon Oncology Research Consortium.Clin Lymphoma Myeloma 2009;9:223-228.
46. Zinzani PL, Tani M, Pulsoni A, et al.A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.Ann Oncol 2012;23:415-420.
47. Van Oers M, Klasa R, Marcus RE, et al.Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial.Blood 2006;108:32953301.
48. Forstpointer R, Unterhalt M, Dreyling M, et al.Maintenance therapy leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophoshamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German low Grade Lymphoma Study Group (GLSG).Blood 2006;108:4003-4008.
49. Hainsworth J, Litchy S, Shaffer D, et al.Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment in patients with indolent non Hodgkin's lymphoma-A randomized phase II trial of the Minnie Pearl Cancer Research Network.J Clin Oncol 2005;23:1088-1095.
50. Ghielmini M, Schmitz S, Cogliatti S, et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.Blood 2004;103:4416-4423.
51. Vidal L, Gafter-Gvili A, Salles G, et al.Rituximab maintenance for the treatment of patients with follicular lymphoma: An updated systematic review and meta-analysis of randomized trials.J Natl Cancer Inst 2011;103:1799-1806.
52. Sebban C, Brice P, Delarue R, et al.Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA study.J Clin Oncol 2008;26:3614-3620.
53. Rohatiner A, Nadler L, Davies A, et al.Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long term follow-up.J Clin Oncol 2007;25:2554-2559.
54. Tarella C, Zanni M, Magni M, et al.Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: A multicenter Gruppo Italiano Terapie innovative nei linfomi survey.J Clin Oncol 2008;26:3166-3175.
55. Arcaini L, Montanari F, Alessandrino EP, et al.Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.Ann Oncol 2008;19:1331-1335.
56. Peters AC, Duan Q, Russell JA, et al.Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: Positive impact of recent rituximab exposure and low-risk follicular lymphoma international prognostic index score.Leuk Lymphoma 2011;52: 2124-2129.
57. Le Gouill S, De Guibert S, Planche L, et al.Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.GELA and GOELAMS. Haematologica 2011;96: 1128-1135.
58. Hoerr AL, Gao F, Hidalgo J, et al.Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.J Clin Oncol 2004;22:45614566.
59. Kang TY, Rybicki LA, Bolwell BJ, et al.Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma.Bone Marrow Transplant 2007;40:973978.
60. Pettengell R, Schmitz N, Gisselbrecht C, et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. ASCO Annual Meeting 2010; Chicago, Abstract 8005.
61. Khouri IF, McLaughlin P, Saliba RM, et al.Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.Blood 2008;111:5530-5536.
62. Piñana JL, Martino R, Gayoso J, et al.GELTAMO Group.Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: Long term follow-up from two prospective multicenter trials. Haematologica 2010;95:1176-1182.
63. Thomson KJ, Morris EC, Milligan D, et al.T-cell depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma J Clin Oncol 2010;28:3695-3700.
64. Avivi I, Montoto S, Canals C, et al.Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.Br J Haematol 2009;147:719-728.
65. Hari P, Carreras J, Zhang MJ, et al.Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.Biol Blood Marrow Transplant 2008;14:236-245.
66. Witzig TE, Gordon LI, Cabanillas F, et al.Randomized controlled trial of yttrium-90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.J Clin Oncol 2002;20:2453-2463.
67. Davies AJ, Rohatiner AZ, Howell S, et al.Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.J Clin Oncol 2004;22:1469-1479.
68. Gordon LI, Molina A, Witzig T, et al.Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20{thorn} B-cell lymphoma: Long-term follow-up of a phase 1/2 study.Blood 2004;103:4429-4431.
69. Gregory SA, Leonard JP, Knox SJ, et al.The iodine 1-131 tositumab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma. (abs.6732).J Clin Oncol 2004;22:615s.
70. NCCN Clinical Practice Guidelines in Oncology (NCCNTM). Non-Hodgkin's Lymphomas. Ves 4.2011. Available at: www.nccn.org. Accessed on November 21, 2011.
71. Mc Namara C, Davies J, Dyer M, et al.On behalf of the British Committee for Standards in Haematology.Guidelines on the investigation and management of follicular lymphoma. Br J Haematol 2012;156:446-467.
72. Dreyling M, Ghielmini M, Marcus R, on behalf of the ESMO Guidelines Working Group.Newly diagnosed and relapsed follicular lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 (Suppl 6):59-63.
73. Oliansky DM, Gordon L, King J, et al.The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: An evidence base review.Biol Blood Marrow Transplant 2010;16:443-468.
74. Vitolo U, Barosi G, Fanti S, et al.Consensus conference on the use of 90-yttrium-ibritumumab tiuxetan therapy in clinical practice.A project of the Italian Society of Hematology. Am J Hematol 2009;85:147-154.
75. Hornberger J, Reyes C, Lubeck D, et al.Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma.Leuk Lymphoma 2008;49:227-236.
76. Braga P, Carvalho S, Gomes M, et al.Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal.Acta Med Port 2010;23:1025-1034.
77. Dundar Y, Bagust A, Hounsome J, et al.Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.Health Technol Assess 2009;13 (Suppl 1):23-28.
78. Soini EJ, Martikainen JA, Nousiainen T.Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: Cost-effectiveness and value of information based on a 5-year follow-up.Ann Oncol 2011;22:1189-1197.
79. Kasteng F, Erlanson M, Hagberg H, et al.Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.Acta Oncol 2008;47:1029-1036.